awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35632548-6B86518D-91BA-4E24-8A77-D6B0736F0757
Q35632548-6B86518D-91BA-4E24-8A77-D6B0736F0757
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35632548-6B86518D-91BA-4E24-8A77-D6B0736F0757
Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.
P2860
Q35632548-6B86518D-91BA-4E24-8A77-D6B0736F0757
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35632548-6B86518D-91BA-4E24-8A77-D6B0736F0757
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
85d92e0c3cce90d6e82ef5bdde0bca472a9d0b29
P2860
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.